FDA recommends approval of Tolvaptan for Hyponatremia « GPCR News

Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

FDA recommends approval of Tolvaptan for Hyponatremia

Posted on June 26, 2008 by crimsoncanary

The FDA Advisory Committee on Cardiovascular and Renal Drugs has voted to recommend the approval of Otsuka’s V2-vasopressin receptor antagonist tolvaptan for the treatment of hyponatremia.

Filed under: gpcr | Tagged: antagonist, Approval, gpcr, Otsuka, regulatory, Vasopressin 2

« Dopamine lead to Impulse-control disorders Merck/Schering withdraw Loratadine/Montelukast NDA and Terminate Collaboration »

Leave a Reply